Leerink downgraded Hologic (HOLX) to Market Perform from Outperform with a price target of $75, down from $80, following the fiscal Q1 report.

Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsMike Watts - Corporate Vice President, ...

The company guided Q2 2025 revenues to be between $995 million and $1.005 billion, with non-GAAP EPS expected in the range of $1 to $1.03. Full-year revenue guidance was revised to $4.05 billion to $4 ...

BTIG analyst Ryan Zimmerman maintained a Hold rating on Hologic (HOLX – Research Report) yesterday. The company’s shares closed yesterday at ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

Explore advancements in women's health through AI, equity, and policy with Mia Keeys of Hologic on I Don’t Care.

The stock's rise snapped a three-day losing streak.

Medical technology company Hologic (NASDAQ:HOLX) in Q4 CY2024, but sales were flat year on year at $1.02 billion. On the ...

Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company ...

MARLBOROUGH, Mass. (AP) — MARLBOROUGH, Mass. (AP) — Hologic Inc. (HOLX) on Wednesday reported fiscal first-quarter profit of $201 million. On a per-share basis, the Marlborough, Massachusetts-based ...

A lunging backhand, a full-court sprint, a last-second volley -- Ons Jabeur’s shot-making instincts were on full display in ...